Results 261 to 270 of about 181,985 (340)

Correction: Evaluation of lung epithelial lining fluid concentrations of lascufloxacin against Streptococcus pneumoniae in a hollow-fiber infection model. [PDF]

J Antibiot (Tokyo)
Kamura HN, Yamaguchi T, Kasama T, Hayashi Y, Hamada M, Matsumoto K, Miyake R, Ishii Y.   +7 more
europepmc   +1 more source

Effects of timing of medication and aging, on pharmacodynamics.

, 1989
Shigeyuki Nakano
openalex   +2 more sources

Nanomaterial‐Based Precision Medicine for Breast Cancer Diagnosis and Treatment

ChemNanoMat, EarlyView.
This research emphasizes the use of targeted precision medicine in the treatment of breast cancer. Through the integration of diagnosis and therapeutic delivery, nanocarriers are designed to selectively target cancer cells, preserving healthy tissue, thereby improving treatment effectiveness and reducing side effects.
Tanaka Ndongwe, Xavier Siwe Noundou, Gauta Gold Matlou, Stéphanie Bessoles, Johanne Seguin, Cyrille Richard, Nathalie Mignet, Yohann Corvis, Bwalya Angel Witika   +8 more
wiley   +1 more source

Comments on "The AI-enhanced surgeon - integrating black-box artificial intelligence in the operating room". [PDF]

Int J Surg
Faezniya M.
europepmc   +1 more source

Pharmacodynamics and pharmacokinetics of ramipril (Hoe 498), an angiotensin converting enzyme (ACE) inhibitor, in dogs

, 1986
Mikio Omosu, Hiroko Yamazaki, Shoryo Hayashi, Takashi Sakaguchi   +3 more
openalex   +1 more source

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

Introducing Digital Pharmacometrics: A Pharmacokinetics (PK)/Pharmacodynamics (PD) Framework for Prescription Digital Therapeutics. [PDF]

Cureus
Lakhan SE.
europepmc   +1 more source

Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and
Jing Zhang, Huixia Zhang, Yajuan Zhang, Shuyuan Liu, Xiaoyun Ge, Haiyue Zhang, Yunfei Li, Cecil Chi‐Keung Chen, Oleg Stepanov, Weifeng Tang, Wenhong Zhang   +10 more
wiley   +1 more source

Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial. [PDF]

BMJ Open
WHO ACTION-III PK PD Collaborators, WHO ACTION-III PK PD.   +1 more
europepmc   +1 more source

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This 2‐part, randomized, placebo‐controlled, double‐blind, Phase 1 study analyzed the pharmacokinetics, safety, and biomarker profile of fezolinetant in healthy Japanese individuals. Part 1: male participants received single doses of placebo or fezolinetant 15 or 60 mg.
Akira Koibuchi, Megumi Iwai, Kanji Komatsu, Kentaro Kuroishi, Mai Shibata, Masako Saito, Jace Nielsen, Jiayin Huang, Shunji Matsuki   +8 more
wiley   +1 more source